MedTrace Logo

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

NCT02112032 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2021-05-05

No results posted yet for this study

Summary

This study is to test how safe it is to give the combination of PEG IFN-α2b (SYLATRON) and MK-3475, an investigational drug, to patients with advanced melanoma. Its effectiveness against melanoma will also be evaluated.

Conditions

Interventions

DRUG

MK-3475

This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.

DRUG

Peginterferon alfa-2b

This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Melanoma Research Alliance

    collaborator OTHER

  • Hassane M. Zarour, MD

    lead OTHER

Principal Investigators

  • Hassane Zarour, MD · UPMC Hillman Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-24
Primary Completion
2019-04-12
Completion
2020-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02112032 on ClinicalTrials.gov